ProShare Advisors’s Agile Therapeutics AGRX Stock Holding History

ProShare Advisors’s Portfolio AGRX Stock Details AGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-9	Closed	-$38K	–	2424
2021 Q1	$38K	Buy	9 +1	+13%	+$5.41K	﹤0.01%	2242
2020 Q4	$43K	Buy	+8	New	+$47.1K	﹤0.01%	2056

Other funds holding AGRX

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

NIM

Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ProShare Advisors's AGRX Position: Q2 2021 in Review

ProShare Advisors sold out of Agile Therapeutics (AGRX) in Q2 2021, closing a stake of 9 shares — an estimated $38K sold.

ProShare Advisors first reported a position in AGRX in Q4 2020 and held it in 2 quarters. The position peaked at $43K in Q4 2020. 64 funds tracked by Wall St. Rank hold AGRX as of Q2 2021.

ProShare Advisors reported no remaining Agile Therapeutics position as of Q2 2021 after selling out during the quarter.
ProShare Advisors sold 9 Agile Therapeutics shares in Q2 2021, an estimated $38K.
ProShare Advisors first reported a position in Agile Therapeutics in Q4 2020 and held it in 2 quarters.
ProShare Advisors's Agile Therapeutics position peaked at $43K in Q4 2020.
64 funds tracked by Wall St. Rank held Agile Therapeutics as of Q2 2021.

Based on ProShare Advisors's 13F filing for Q2 2021, filed 13 Aug 2021.